Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

Respiratory Syncytial Virus (RSV) is a highly contagious respiratory illness that primarily affects infants and older adults, ...

The UKHSA is behind the new warning as a raft of illnesses, including flu, COVID, RSV, norovirus and hMPV, spread across the ...

As of Jan. 20, the CDC reports that RSV activity has peaked in most of the U.S., particularly among young children—a group ...

It spreads through inhalation or contact with the fluids from an infected person's coughs or sneezes. 2 While often linked to ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

The Health Department of Northwest Michigan is reporting an increase in respiratory illnesses across Antrim, Charlevoix, ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.